Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 4619 | 6.84 |
09:34 ET | 2605 | 6.43 |
09:36 ET | 700 | 6.475 |
09:38 ET | 6850 | 6.42 |
09:39 ET | 900 | 6.33 |
09:41 ET | 4708 | 6.44 |
09:43 ET | 1176 | 6.485 |
09:45 ET | 2099 | 6.45 |
09:48 ET | 100 | 6.42 |
09:50 ET | 934 | 6.42 |
09:52 ET | 700 | 6.41 |
09:54 ET | 10595 | 6.45 |
09:56 ET | 3007 | 6.5 |
09:57 ET | 200 | 6.505 |
09:59 ET | 600 | 6.5 |
10:01 ET | 100 | 6.52 |
10:03 ET | 3531 | 6.5 |
10:06 ET | 258 | 6.49 |
10:08 ET | 1000 | 6.515 |
10:10 ET | 480 | 6.515 |
10:12 ET | 1000 | 6.59 |
10:14 ET | 300 | 6.62 |
10:15 ET | 1100 | 6.59 |
10:17 ET | 600 | 6.55 |
10:19 ET | 100 | 6.575 |
10:21 ET | 9780 | 6.6 |
10:24 ET | 100 | 6.615 |
10:26 ET | 27150 | 6.6 |
10:28 ET | 300 | 6.6 |
10:30 ET | 9498 | 6.65 |
10:32 ET | 3143 | 6.66 |
10:33 ET | 12911 | 6.66 |
10:35 ET | 14917 | 6.8 |
10:39 ET | 2867 | 6.71 |
10:42 ET | 2490 | 6.66 |
10:44 ET | 2217 | 6.63 |
10:46 ET | 1801 | 6.63 |
10:48 ET | 1642 | 6.65 |
10:50 ET | 1788 | 6.65 |
10:51 ET | 1403 | 6.645 |
10:53 ET | 2917 | 6.63 |
10:55 ET | 4963 | 6.655 |
10:57 ET | 2157 | 6.64 |
11:00 ET | 3562 | 6.66 |
11:02 ET | 2731 | 6.68 |
11:04 ET | 3866 | 6.57 |
11:06 ET | 1858 | 6.52 |
11:08 ET | 1666 | 6.51 |
11:09 ET | 2070 | 6.49 |
11:11 ET | 2034 | 6.46 |
11:13 ET | 2518 | 6.51 |
11:15 ET | 1228 | 6.49 |
11:18 ET | 2619 | 6.51 |
11:20 ET | 1617 | 6.49 |
11:22 ET | 2484 | 6.49 |
11:24 ET | 2668 | 6.46 |
11:26 ET | 2011 | 6.48 |
11:27 ET | 1200 | 6.55 |
11:29 ET | 749 | 6.52 |
11:31 ET | 1030 | 6.535 |
11:33 ET | 2274 | 6.575 |
11:36 ET | 400 | 6.52 |
11:38 ET | 600 | 6.51 |
11:40 ET | 1781 | 6.565 |
11:42 ET | 269 | 6.54 |
11:44 ET | 600 | 6.54 |
11:45 ET | 1849 | 6.55 |
11:47 ET | 125 | 6.55 |
11:49 ET | 524 | 6.52 |
11:51 ET | 500 | 6.52 |
11:54 ET | 1748 | 6.555 |
11:56 ET | 200 | 6.56 |
11:58 ET | 427 | 6.55 |
12:00 ET | 4073 | 6.54 |
12:02 ET | 200 | 6.54 |
12:03 ET | 200 | 6.55 |
12:05 ET | 2100 | 6.58 |
12:07 ET | 801 | 6.56 |
12:09 ET | 100 | 6.56 |
12:12 ET | 200 | 6.55 |
12:14 ET | 400 | 6.53 |
12:16 ET | 405 | 6.53 |
12:18 ET | 600 | 6.53 |
12:20 ET | 1300 | 6.55 |
12:21 ET | 300 | 6.55 |
12:23 ET | 600 | 6.55 |
12:25 ET | 300 | 6.54 |
12:27 ET | 1565 | 6.545 |
12:30 ET | 200 | 6.55 |
12:32 ET | 600 | 6.56 |
12:34 ET | 322 | 6.55 |
12:36 ET | 933 | 6.55 |
12:38 ET | 1159 | 6.56 |
12:39 ET | 400 | 6.54 |
12:41 ET | 1315 | 6.54 |
12:43 ET | 712 | 6.54 |
12:45 ET | 100 | 6.545 |
12:48 ET | 26610 | 6.72 |
12:50 ET | 1835 | 6.69 |
12:52 ET | 200 | 6.71 |
12:54 ET | 1380 | 6.735 |
12:56 ET | 300 | 6.735 |
12:57 ET | 800 | 6.72 |
12:59 ET | 2185 | 6.71 |
01:01 ET | 2396 | 6.7 |
01:03 ET | 1475 | 6.71 |
01:06 ET | 700 | 6.7 |
01:08 ET | 800 | 6.73 |
01:10 ET | 2590 | 6.72 |
01:12 ET | 600 | 6.7 |
01:14 ET | 1300 | 6.7 |
01:15 ET | 900 | 6.7 |
01:17 ET | 1775 | 6.739 |
01:19 ET | 806 | 6.71 |
01:21 ET | 1100 | 6.7 |
01:24 ET | 800 | 6.7 |
01:26 ET | 800 | 6.7 |
01:28 ET | 700 | 6.7 |
01:30 ET | 1461 | 6.71 |
01:32 ET | 1706 | 6.71 |
01:33 ET | 1861 | 6.7 |
01:35 ET | 886 | 6.7 |
01:37 ET | 1681 | 6.7 |
01:39 ET | 1100 | 6.725 |
01:42 ET | 3018 | 6.71 |
01:44 ET | 1056 | 6.71 |
01:46 ET | 941 | 6.7 |
01:48 ET | 100 | 6.7 |
01:50 ET | 1100 | 6.76 |
01:51 ET | 200 | 6.76 |
01:55 ET | 200 | 6.74 |
01:57 ET | 100 | 6.74 |
02:00 ET | 100 | 6.74 |
02:02 ET | 300 | 6.76 |
02:04 ET | 200 | 6.74 |
02:06 ET | 1500 | 6.78 |
02:08 ET | 800 | 6.795 |
02:09 ET | 300 | 6.82 |
02:11 ET | 200 | 6.8 |
02:13 ET | 400 | 6.81 |
02:15 ET | 3700 | 6.84 |
02:18 ET | 400 | 6.845 |
02:20 ET | 200 | 6.849 |
02:22 ET | 100 | 6.83 |
02:24 ET | 200 | 6.83 |
02:26 ET | 100 | 6.85 |
02:27 ET | 1860 | 6.85 |
02:29 ET | 100 | 6.85 |
02:31 ET | 100 | 6.855 |
02:33 ET | 1000 | 6.88 |
02:36 ET | 700 | 6.9 |
02:38 ET | 985 | 6.89 |
02:40 ET | 400 | 6.91 |
02:42 ET | 1159 | 6.915 |
02:44 ET | 300 | 6.91 |
02:45 ET | 300 | 6.9 |
02:47 ET | 1055 | 6.915 |
02:49 ET | 664 | 6.92 |
02:51 ET | 8607 | 7.02 |
02:54 ET | 1988 | 6.98 |
02:56 ET | 1750 | 6.965 |
02:58 ET | 253 | 6.979 |
03:00 ET | 400 | 6.95 |
03:02 ET | 100 | 6.965 |
03:03 ET | 400 | 6.95 |
03:05 ET | 1306 | 6.97 |
03:07 ET | 200 | 6.97 |
03:09 ET | 1500 | 6.99 |
03:12 ET | 800 | 7.02 |
03:14 ET | 1700 | 7.07 |
03:16 ET | 1406 | 7.075 |
03:18 ET | 4255 | 7.02 |
03:20 ET | 2100 | 7.03 |
03:21 ET | 1421 | 7.09 |
03:23 ET | 1200 | 7.07 |
03:25 ET | 2900 | 7.09 |
03:27 ET | 2861 | 7.14 |
03:30 ET | 3400 | 7.12 |
03:32 ET | 3362 | 7.13 |
03:34 ET | 3539 | 7.14 |
03:36 ET | 4639 | 7.1 |
03:38 ET | 5364 | 7.14 |
03:39 ET | 2895 | 7.13 |
03:41 ET | 5439 | 7.05 |
03:43 ET | 3930 | 7 |
03:45 ET | 900 | 6.96 |
03:48 ET | 2233 | 6.95 |
03:50 ET | 1320 | 6.94 |
03:52 ET | 3117 | 6.94 |
03:54 ET | 5052 | 6.91 |
03:56 ET | 3195 | 6.93 |
03:57 ET | 4179 | 6.92 |
03:59 ET | 64993 | 6.91 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 454.4M | -3.8x | --- |
LENZ Therapeutics Inc | 451.7M | -1.1x | --- |
Larimar Therapeutics Inc | 447.9M | -7.6x | --- |
Grail Inc | 444.2M | -7.8x | --- |
Corbus Pharmaceuticals Holdings Inc | 464.8M | -6.3x | --- |
Altimmune Inc | 443.5M | -4.0x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $454.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.81 |
Book Value | $4.08 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.